Immucell (ICCC) AI Stock Analysis

Company Guidance

Guidance from the call focused on materially expanding and de‑risking supply while improving costs and yields: management plans an ~ $8.0M, two‑phase capacity program (a $3.5M freeze‑drying phase to be completed in H1 2027 and ~ $4.5M liquids phase targeted by year‑end 2027) that it expects will more than triple current capacity, shorten processing time from 2–3 months to under 1 month, and improve long‑term product cost; the company is on track to produce nearly 1.0 million more manufacturing units in 2026 versus 2025, financing the majority with cash on hand ($8.9M as of 6/30/26) and operating cash (may use credit line), while continuing yield work (colostrum is ~50% of product cost). Recent operating/financial context cited with that guidance: Q1 production exceeded 450,000 units/month and Q2 averaged ~350,000 units/month (seasonal/planned), Q2 product sales $7.2M (+11.5% YoY) and H1 product sales $17.5M (+20.9% YoY), gross margin 33.9% (vs 43.7% LY) with an 11.1‑point sequential decline driven ~7.5 points by lower output, 2.1 points by ~$150k scrap and 1.9 points by the Re‑Tain cost shift, adjusted EBITDA of $2.7M in Q2 and $5.4M for H1 (both include a $2M legal settlement), net income of $1.8M ($0.20/share) in Q2 and $3.8M for H1, inventory $9.1M and working capital $16.6M, distributor out‑the‑door volumes +21% Q1 / +28% Q2 (24% H1), and U.S. market share for First Defense rising from ~15% in Dec‑2025 to ~19% in June‑2026 (share of spend ~29% to ~38%).